Hervé Pierre-Louis, Plaquet Camille, Assoun Noémie, Oreal Nathalie, Gaulme Laetitia, Perrin Audrey, Bouzereau Adeline, Dhelft Véronique, Labernardière Jean-Louis, Mondoulet Lucie, Sampson Hugh A
Research and Innovation, DBV Technologies, Montrouge, France.
Research and Innovation, DBV Technologies, New York, NY, United States.
Front Immunol. 2021 Mar 26;12:609029. doi: 10.3389/fimmu.2021.609029. eCollection 2021.
Due to its richness in antigen presenting cells, e.g., dendritic cells (DC), the skin has been identified as a promising route for immunotherapy and vaccination. Several years ago, a skin delivery system was developed based on epicutaneous patches allowing the administration of antigen through intact skin. Using mouse models, we have shown that epicutaneous allergen application leads to a rapid uptake and transport of allergen-positive cells to skin-draining lymph nodes (LN). This occurred primarily in animals previously sensitized to the same allergen. In that context, we sought to better understand the role of the specific preexisting immunity in allergen capture by skin DC and their subsequent migration to LN. Specifically, we investigated the role of humoral immunity induced by sensitization and the involvement of IgG Fc receptors (FcγR). Epicutaneous patches containing fluorescently-labeled ovalbumin (OVA) were applied to naïve mice that had previously received either sera or purified IgG isolated from OVA-sensitized mice. To investigate the involvement of FcγR, animals received 2.4G2 (anti-FcγRII/RIII) blocking antibody, 24 hours before patch application. Mice that received sera or purified IgG originating from OVA-sensitized mice showed an increase in the quantity of OVA-positive DC in skin and LN. Moreover, the blockade of FcγR reduced the number of OVA-positive DC in LN to a level similar to that observed in naïve animals. Overall, these results demonstrate that preexisting specific-IgG antibodies are involved in allergen capture by skin DC following EPIT through the involvement of antigen-specific IgG-FcγR.
由于皮肤富含抗原呈递细胞,如树突状细胞(DC),已被确定为免疫治疗和疫苗接种的一条有前景的途径。几年前,基于透皮贴剂开发了一种皮肤给药系统,可通过完整皮肤给药抗原。利用小鼠模型,我们已表明经皮应用变应原可导致变应原阳性细胞快速摄取并转运至引流皮肤的淋巴结(LN)。这主要发生在先前对相同变应原致敏的动物中。在此背景下,我们试图更好地理解特定的预先存在的免疫在皮肤DC捕获变应原及其随后迁移至LN中的作用。具体而言,我们研究了致敏诱导的体液免疫的作用以及IgG Fc受体(FcγR)的参与情况。将含有荧光标记卵清蛋白(OVA)的透皮贴剂应用于先前接受过从OVA致敏小鼠分离的血清或纯化IgG的未致敏小鼠。为了研究FcγR的参与情况,在贴剂应用前24小时给动物注射2.4G2(抗FcγRII/RIII)阻断抗体。接受来自OVA致敏小鼠的血清或纯化IgG的小鼠,其皮肤和LN中OVA阳性DC的数量增加。此外,FcγR的阻断将LN中OVA阳性DC的数量减少至与未致敏动物中观察到的水平相似。总体而言,这些结果表明,预先存在的特异性IgG抗体通过抗原特异性IgG-FcγR的参与,在经皮免疫治疗(EPIT)后参与皮肤DC捕获变应原。